Castleman Disease Collaborative Network Biobank ("Castlebank")
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02871050|
Recruitment Status : Withdrawn (An alternative Biobank Project was initiated.)
First Posted : August 18, 2016
Last Update Posted : July 31, 2018
|Condition or disease||Intervention/treatment|
|Castleman Disease Castleman's Disease Giant Lymph Node Hyperplasia Angiofollicular Lymph Hyperplasia Angiofollicular Lymph Node Hyperplasia Angiofollicular Lymphoid Hyperplasia GLNH Hyperplasia Giant Lymph Node||Other: Sample Collection|
The CDCN proposes to establish a biobank and associated clinical data for Castleman disease. Tissue and fluid (blood and saliva) samples will be collected both prospectively and retrospectively. Blood or saliva samples may also be collected from relatives of Castleman patients. Because of the scarcity of these samples, it will be necessary to make efforts to access all available cases. Many cases will occur at hospitals that do not have an existing relationship with the CDCN and may not have experience with tissue procurement; however, this is the only way to obtain the vast majority of samples. Samples may be used immediately, banked for future use, or further processed into DNA, cell lines, tissue microarrays, etc.
The samples will be stored at Precision for Medicine, a biorepository company that specializes in collection, processing, storage and distribution of biospecimens. Only researchers (US or international) who have applied to the CDCN and have been approved by the Biobank Advisory Board will be eligible to access biospecimens and/or data. The Biobank Advisory Board will be comprised of clinicians and scientists with experience in clinical and investigational practices in Castleman Disease.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research|
|Study Start Date :||June 2016|
|Actual Primary Completion Date :||June 2018|
|Actual Study Completion Date :||June 2018|
Castleman Disease Patients
Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
Other: Sample Collection
Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
- Samples Collected [ Time Frame: 3 years ]Number of samples collected across different subgroups (e.g. blood products, lymph node)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02871050
|United States, Pennsylvania|
|Castleman Disease Collaborative Network|
|Philadelphia, Pennsylvania, United States, 19146|
|Principal Investigator:||David C Fajgenbaum, MD, MBA, MSc||Executive Director of Castleman Disease Collaborative Network|